Charlotte Granhall1, Morten Donsmark1, Thalia M Blicher1, Georg Golor2, Flemming L Søndergaard3, Mette Thomsen1, Tine A Bækdal4. 1. Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark. 2. Early Phase Clinical Unit-Berlin, Parexel International GmbH, Klinikum Westend-Haus 18, Spandauer Damm 130, 14050, Berlin, Germany. 3. Novo Nordisk A/S, Alfred Nobels Vej 27, 9220, Aalborg Ø, Denmark. 4. Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark. tabq@novonordisk.com.
Abstract
BACKGROUND:Oral semaglutide is a novel tablet containing the human glucagon-like peptide-1 (GLP‑1) analogue semaglutide, co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The safety and pharmacokinetics of oral semaglutide were investigated in two randomised, double-blind, placebo-controlled trials. METHODS: In a single-dose, first-in-human trial, 135 healthy males receivedoral semaglutide (2-20 mg semaglutide co-formulated with 150-600 mg SNAC) or placebo with SNAC. In a 10-week, once-daily, multiple-dose trial, 84 healthy males received20 or 40 mg oral semaglutide (with 300 mg SNAC), placebo, or placebo with SNAC, and 23 males with type 2 diabetes (T2D) received40 mg oral semaglutide (with 300 mg SNAC), placebo, or placebo with SNAC. RESULTS:Oral semaglutide was safe and well-tolerated in both trials. The majority of adverse events (AEs) were mild, with the most common AEs being gastrointestinal disorders. In the single-dose trial, semaglutide exposure was highest when co-formulated with 300 mg SNAC. In the multiple-dose trial, semaglutide exposure was approximately twofold higher with 40 versus 20 mg oral semaglutide in healthy males, in accordance with dose proportionality, and was similar between healthy males and males with T2D. The half-life of semaglutide was approximately 1 week in all groups. CONCLUSION: The safety profile of oral semaglutide was as expected for the GLP-1 receptor agonist drug class. Oral semaglutide co-formulated with 300 mg SNAC was chosen for further clinical development. The pharmacokinetic results supported that oral semaglutide is suitable for once-daily dosing. CLINICALTRIALS. GOV IDENTIFIERS: NCT01037582, NCT01686945.
RCT Entities:
BACKGROUND: Oral semaglutide is a novel tablet containing the humanglucagon-like peptide-1 (GLP‑1) analogue semaglutide, co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The safety and pharmacokinetics of oral semaglutide were investigated in two randomised, double-blind, placebo-controlled trials. METHODS: In a single-dose, first-in-human trial, 135 healthy males received oral semaglutide (2-20 mg semaglutide co-formulated with 150-600 mg SNAC) or placebo with SNAC. In a 10-week, once-daily, multiple-dose trial, 84 healthy males received 20 or 40 mg oral semaglutide (with 300 mg SNAC), placebo, or placebo with SNAC, and 23 males with type 2 diabetes (T2D) received 40 mg oral semaglutide (with 300 mg SNAC), placebo, or placebo with SNAC. RESULTS: Oral semaglutide was safe and well-tolerated in both trials. The majority of adverse events (AEs) were mild, with the most common AEs being gastrointestinal disorders. In the single-dose trial, semaglutide exposure was highest when co-formulated with 300 mg SNAC. In the multiple-dose trial, semaglutide exposure was approximately twofold higher with 40 versus 20 mg oral semaglutide in healthy males, in accordance with dose proportionality, and was similar between healthy males and males with T2D. The half-life of semaglutide was approximately 1 week in all groups. CONCLUSION: The safety profile of oral semaglutide was as expected for the GLP-1 receptor agonist drug class. Oral semaglutide co-formulated with 300 mg SNAC was chosen for further clinical development. The pharmacokinetic results supported that oral semaglutide is suitable for once-daily dosing. CLINICALTRIALS. GOV IDENTIFIERS: NCT01037582, NCT01686945.
Authors: B Bittner; C McIntyre; H Tian; K Tang; N Shah; W Phuapradit; H Ahmed; H Chokshi; M Infeld; N Fotaki; H Ma; A Portron; P Jordan; J Schmidt Journal: Pharmazie Date: 2012-03 Impact factor: 1.267
Authors: Stephen T Buckley; Tine A Bækdal; Andreas Vegge; Stine J Maarbjerg; Charles Pyke; Jonas Ahnfelt-Rønne; Kim G Madsen; Susanne G Schéele; Tomas Alanentalo; Rikke K Kirk; Betty L Pedersen; Rikke B Skyggebjerg; Andrew J Benie; Holger M Strauss; Per-Olof Wahlund; Simon Bjerregaard; Erzsébet Farkas; Csaba Fekete; Flemming L Søndergaard; Jeanett Borregaard; Marie-Louise Hartoft-Nielsen; Lotte Bjerre Knudsen Journal: Sci Transl Med Date: 2018-11-14 Impact factor: 17.956
Authors: Melanie Davies; Thomas R Pieber; Marie-Louise Hartoft-Nielsen; Oluf K H Hansen; Serge Jabbour; Julio Rosenstock Journal: JAMA Date: 2017-10-17 Impact factor: 56.272
Authors: Stephanie Niman; Jennifer Hardy; Rebecca F Goldfaden; Jessica Reid; Mae Sheikh-Ali; David Sutton; Rushab Choksi Journal: Drugs R D Date: 2021-03-26